Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
Dr. Barry M. Trost, Tamaki Professor of Humanities and Sciences in the chemistry department at Stanford University, is a world renowned organic chemist and a fellow of the U.S. National Academy of Sciences. Professor Barry M. Trost's professional interests include asymmetric allylic alkylation and efficient enantioselective synthesis. He has made great contributions to the modern synthetic organic chemistry and green chemistry. Many widely used chemistry reactions, such as the Trost asymmetric allylic alkylation, Tsuji-Trost reaction and the Trost ligand, are named after him.
Professor Trost studied at the University of Pennsylvania and received his Ph.D. from the Massachusetts Institute of Technology in 1965. He was a professor at the University of Wisconsin-Madison from 1965 until his appointment to Stanford University in 1987. Professor Trost has more than 820 scientific publications, over 320 lectures at various national and international meetings, and over 40 worldwide awards and honors.
As another luminary speaker of WuXi PharmaTech Science Seminar Series, Professor Trost gave the WuXi scientists two lectures titled "New Synthetic Strategies to Bioactive Products" and "On Inventing Reactions for Atom Economy." Professor Trost captivated the audience from beginning to end during the lectures and answered questions from the packed crowd.
"This is my first time to give a lecture to a pharmaceutical service company in China. I am very impressed by WuXi's Science Seminar Series program as well as the research capability and scientific acumen of WuXi's young scientists. Talents are absolutely the key to success for any business, especially for WuXi which provides high quality research and development services to global life science companies," commented Professor Barry M. Trost.
"We are very privileged to have Dr. Trost share his brilliant expertise with our young scientists," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "As we broaden our R&D service scope our success very much depends on the quality of our scientists. Investing in people is and will continue to be one of our top strategies."
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com/ .
For more information, please contact: Sherry Shao Tel: +86-21-5046-4002 Email: firstname.lastname@example.org
CONTACT: Sherry Shao of WuXi PharmaTech, +86-21-5046-4002, or email@example.com
Web Site: http://www.wuxipharmatech.com/
|Printer friendly Cite/link Email Feedback|
|Date:||May 21, 2008|
|Previous Article:||Oil Refineries' Board Approves an Outline For Potential Acquisition of Balance of Carmel Olefins.|
|Next Article:||WestLB Mellon Asset Management Selects BNY Mellon Asset Servicing to Provide Luxembourg Fund Services For its Longitude SICAV.|